Home Drug IndexClinical Monograph

Ritodrine Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Navigation

DRUG NAME: Ritodrine

Therapeutic Class: Uterine relaxant (tocolytic)

Subclass: Beta-2 adrenergic agonist

Speciality: Obstetrics & Gynaecology

Schedule (India): Schedule H

Route(s): Intravenous (IV)

Formulations Available in India:

Injection: 50 mg/10 mL ampoule (5 mg/mL)

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

▶ Preterm Labour (Tocolysis)

Used for delaying preterm birth between 24–33 weeks of gestation to allow antenatal corticosteroid administration or maternal transfer to higher-level care facility.

IV Infusion Protocol:

Parameter	Recommendation
Starting dose	50 mcg/min IV infusion
Titration	Increase by 50 mcg/min every 10 minutes until contractions cease or side effects limit further increase
Usual maintenance dose	150–350 mcg/min (individualised to lowest effective dose maintaining tocolysis)
Maximum dose	350 mcg/min

Preparation:

Dilute 150 mg (3 ampoules) in 500 mL of 5% Dextrose or Normal Saline
Final concentration: 300 mcg/mL
Use infusion pump for accurate delivery

Clinical Notes:

INPATIENT USE ONLY — requires continuous cardiopulmonary monitoring
Discontinue immediately if:
- Maternal pulse exceeds 140 bpm
- Significant hypotension or chest pain develops
- Signs of pulmonary oedema appear
- Oxygen saturation drops below 95%
Duration typically limited to 48–72 hours
Specialist obstetric supervision mandatory

Secondary Indications — Adults Only (Off-label)

Not applicable. No off-label indications supported in Indian practice.

PAEDIATRIC DOSING (Specialist Only)

Not applicable — Ritodrine is not indicated for paediatric patients.

RENAL ADJUSTMENT

Renal Function	Recommendation
Mild–Moderate impairment	No specific dose adjustment required; monitor fluid balance closely
Severe impairment	Use with caution — risk of drug accumulation and fluid retention; slower titration advised
Haemodialysis	No specific data available

HEPATIC ADJUSTMENT


Child-Pugh Class	Score	Recommendation
Class A (Mild)	5–6 points	Use with caution; standard starting dose acceptable; titrate slowly based on response; monitor for adverse effects
Class B (Moderate)	7–9 points	Use with caution; consider lower maintenance doses; slower titration advised; enhanced cardiopulmonary monitoring required
Class C (Severe)	10–15 points	Avoid if possible; use only under specialist supervision with intensive monitoring; significant risk of drug accumulation and altered response

Clinical Notes:

Ritodrine is metabolised hepatically; impaired liver function may prolong half-life and increase systemic exposure
No formal pharmacokinetic studies in hepatic impairment; recommendations based on pharmacological principles
Monitor more frequently for tachycardia, tremor, and metabolic effects in patients with hepatic dysfunction

CONTRAINDICATIONS

Antepartum haemorrhage requiring delivery (placenta praevia, placental abruption)
Eclampsia or severe pre-eclampsia
Intrauterine fetal death
Lethal fetal anomalies incompatible with life
Intrauterine infection (chorioamnionitis)
Maternal cardiac disease (arrhythmias, ischaemic heart disease, valvular disease)
Uncontrolled hyperthyroidism
Known hypersensitivity to ritodrine or other sympathomimetic amines
Cervical dilatation >4 cm (relative — limited benefit)
Gestational age <24 weeks or >33 weeks (outside therapeutic window)

CAUTIONS

Diabetes mellitus — may cause significant hyperglycaemia and ketoacidosis; monitor glucose frequently
Multiple gestation — increased risk of pulmonary oedema
High fluid volume administration — restrict IV fluids to minimise pulmonary oedema risk
Concurrent corticosteroid use — significantly increases pulmonary oedema risk
History of cardiac arrhythmias — risk of atrial fibrillation, SVT
Hypokalaemia risk — monitor serum potassium
Asthma — rare paradoxical bronchospasm may occur
Anaemia — may mask symptoms of blood loss
Migraine — beta-agonists may trigger attacks

PREGNANCY

Aspect	Details
Overall safety	Not teratogenic; intended for short-term use (48–72 hours) in pregnancy
When to use	Specialist obstetric use only for delaying preterm delivery to allow corticosteroid administration or maternal transfer; gestational age 24–33 weeks
Preferred alternatives	Nifedipine (oral tocolytic — better safety profile, now preferred first-line in many Indian centres); Atosiban (if available)
Monitoring required	Maternal: Pulse (target <140 bpm), BP, SpO2, blood glucose, serum potassium, fluid balance, respiratory rate, chest auscultation for pulmonary oedema. Fetal: Continuous CTG monitoring for fetal heart rate and uterine contractions

LACTATION

Aspect	Details
Compatibility	Not studied; avoid if possible in immediate postpartum period
Expected levels in milk	Unknown
Preferred alternatives	Nifedipine or atosiban if uterine relaxation needed postpartum
Infant monitoring	If exposure occurs: observe infant for tachycardia, irritability, feeding difficulties (though unlikely given short half-life)

ELDERLY

Not applicable — Ritodrine is not indicated in the elderly population.

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect/Risk	Management
MAO inhibitors	Severe risk of hypertensive crisis due to potentiation of sympathomimetic effects	CONTRAINDICATED — avoid concurrent use
Beta-blockers (propranolol, labetalol, atenolol)	Antagonism of tocolytic effect; risk of unopposed alpha-mediated hypertension and paradoxical bronchospasm	Avoid concurrent use
Halogenated anaesthetics (halothane, enflurane)	Increased risk of serious cardiac arrhythmias due to myocardial sensitisation	Avoid concurrent use; discontinue ritodrine before general anaesthesia if possible
Other sympathomimetic agents	Additive cardiovascular toxicity	Avoid combination

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect/Risk	Management
Corticosteroids (betamethasone, dexamethasone)	Significantly increased risk of pulmonary oedema when used concurrently for fetal lung maturity	Restrict IV fluids to <1.5–2 L/24 hours; monitor closely for respiratory symptoms
Non-potassium-sparing diuretics (furosemide)	Additive hypokalaemia risk	Monitor serum potassium; supplement if needed
Insulin and oral antidiabetic agents	Ritodrine causes hyperglycaemia — may require increased antidiabetic doses	Monitor blood glucose every 2–4 hours; adjust diabetes therapy accordingly
Magnesium sulphate	Additive cardiovascular depression; increased pulmonary oedema risk	Avoid concurrent use if possible; if unavoidable, use with extreme caution and enhanced monitoring
Digoxin	Hypokalaemia from ritodrine may increase digoxin toxicity	Monitor potassium and digoxin levels

COMMON ADVERSE EFFECTS

Maternal tachycardia (very common, dose-related)
Palpitations
Tremor (fine tremor of hands)
Nausea and vomiting
Headache
Hyperglycaemia
Hypokalaemia
Flushing
Anxiety or restlessness
Chest discomfort

SERIOUS ADVERSE EFFECTS

Adverse Effect	Notes
Pulmonary oedema	Most serious complication; risk increased with fluid overload, corticosteroids, multiple gestation; requires immediate discontinuation, oxygen, diuretics, and supportive care
Cardiac arrhythmias	Atrial fibrillation, supraventricular tachycardia, ventricular ectopics; discontinue immediately
Myocardial ischaemia	Chest pain with ECG changes; discontinue and evaluate
Severe hypotension	Reduce rate or discontinue; IV fluids if hypovolaemic
Diabetic ketoacidosis	Especially in diabetic patients; requires urgent treatment
Fetal tachycardia	May indicate excessive maternal dosing; reduce infusion rate
Cerebral or retinal haemorrhage	Rare; associated with severe hypertension

MONITORING REQUIREMENTS

Timing	Parameters
Baseline	Maternal: Blood pressure, heart rate, ECG, respiratory rate, SpO2, blood glucose, serum electrolytes (K+, Mg2+), fluid status assessment, chest auscultation. Fetal: CTG for fetal heart rate and uterine activity
During infusion	Continuous: Maternal HR (stop if >140 bpm), BP, SpO2, respiratory rate, CTG. Every 2–4 hours: Blood glucose, fluid input/output balance. Every 6–12 hours: Serum potassium. Chest auscultation every 4–6 hours for pulmonary oedema
Long-term (if >48 hours)	Daily: Electrolytes, glucose, fluid balance, ECG if indicated. Discontinue as soon as clinically appropriate

Discontinuation Criteria:

Maternal HR >140 bpm sustained
SpO2 <95% or respiratory distress
Pulmonary oedema (crackles, dyspnoea)
Chest pain or ECG changes
Severe hypotension
Significant hypokalaemia (<3.0 mmol/L)

BRANDS AVAILABLE IN INDIA

Yutopar Injection (Abbott)
Generic ritodrine (institutional/government supply)

PRICE RANGE (INR)

Formulation	Price Range	Notes
50 mg/10 mL ampoule	₹120–₹200 per ampoule	Brand-dependent

Not under NLEM price control
Typically included in government obstetric drug protocols
May be subsidised in public healthcare settings

CLINICAL PEARLS

Ritodrine is no longer first-line in India — Nifedipine (oral) has a better safety profile with fewer cardiovascular side effects and is now preferred in many Indian centres for tocolysis.
Strict fluid restriction is critical — Limit total IV fluids to <1.5–2 L/24 hours to minimise pulmonary oedema risk, especially when corticosteroids are co-administered.
Heart rate is your guide — Discontinue immediately if maternal pulse exceeds 140 bpm or patient reports chest discomfort; do not push dose higher.
Short-term use only — Maximum benefit is in the 48-hour window to allow antenatal corticosteroid effect; prolonged use increases risks without clear benefit.
Watch for pulmonary oedema — Most common serious adverse effect; higher risk with multiple gestation, concurrent steroids, and excessive fluid administration. Early signs include tachypnoea, cough, and declining SpO2.
Glucose and potassium monitoring essential — Expect hyperglycaemia (especially in diabetics requiring insulin adjustment) and hypokalaemia (may need potassium supplementation).

VERSION

RxIndia v0.9 — 14 Jan 2025

REFERENCES

CDSCO approved product information
Indian Pharmacopoeia
ICMR Guidelines on Preterm Birth (2022)
AIIMS Obstetric Drug Protocol
API Textbook of Medicine
Harrison’s Principles of Internal Medicine
WHO Recommendations on Interventions to Improve Preterm Birth Outcomes (supportive)
FOGSI Guidelines (supportive)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.